Table 2. Adverse Events.

Type of adverse event	Number of events	Time period	Dose Cohort(s)	SAE?
Vomiting due to gastrointestinal infection	1	During treatment	50g	No
Hip pain	1	During treatment	50g	No
Vaso-occlusive pain episode with hospitalization	2	During treatment	50g, 100g	Yes
Shortness of breath with hospitalization	1	After treatment	100g	Yes
Increased proteinuria	2	During treatment	100g, 150g	No
Abdominal pain, vaso-occlusive pain episode, and QT prolongation, with hospitalization	1	During treatment	150g	Yes
Chest pain with hospitalization	1	After treatment	150g	Yes

All adverse events were not thought to be related to BSH consumption. Adverse events occurred as follows: one patient experienced both the vaso-occlusive pain episode (50g) and abdominal pain (150g) events. Another patient experienced the vaso-occlusive pain episode (100g), shortness of breath (100g), and chest pain (150g) episodes, and a different individual experienced both incidences of proteinuria (100g, 150g). All other events occurred within other, single patients.